We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05223699
Recruitment Status : Terminated (Sponsor Decision)
First Posted : February 4, 2022
Last Update Posted : February 9, 2023
Information provided by (Responsible Party):
Magenta Therapeutics, Inc.

Brief Summary:
This research study is designed to selectively deplete CD117-positive cells from participants with AML and MDS-EB.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Myelodysplasia Biological: MGTA-117 Phase 1

Detailed Description:
This is a multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential anti-leukemia activity and to establish the minimum safe and biologically-effective dose of a single dose of MGTA-117 in relapsed/refractory (R/R) CD117+ AML participants and participants with MDS-EB. The study consists of escalating single-dose cohorts using a standard 3+3 design.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II, Dose-Escalation Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)
Actual Study Start Date : February 14, 2022
Actual Primary Completion Date : February 2, 2023
Actual Study Completion Date : February 2, 2023

Arm Intervention/treatment
Experimental: Single dose MGTA-117
Dosing of MGTA-117 prepared and administered by IV infusion.
Biological: MGTA-117
MGTA-117 will be administered as an IV infusion

Primary Outcome Measures :
  1. Incidence rate of treatment emergent adverse events (TEAEs) leading to study drug discontinuation [ Time Frame: 21 days ]
  2. Incidence rate of treatment emergent >= Grade 3 clinical laboratory abnormalities as assessed by CTCAE v5.0 [ Time Frame: 21 days ]
  3. Assess the clinically significant changes from baseline in vital signs, ECGs and laboratory parameters [ Time Frame: 21 days ]
  4. Pharmacokinetics profile of MGTA-117 [ Time Frame: 21 days ]
    Investigate area under the curve (AUC)

  5. Pharmacokinetics profile of MGTA-117 [ Time Frame: 21 days ]
    Investigate maximum plasma concentration (Cmax)

  6. Pharmacokinetics profile of MGTA-117 [ Time Frame: 21 days ]
    Investigate time of maximum concentration (Tmax)

  7. Pharmacokinetics profile of MGTA-117 [ Time Frame: 21 days ]
    Investigate the half-life (t1/2)

  8. Pharmacokinetics profile of MGTA-117 [ Time Frame: 21 days ]
    Investigate the plasma concentration

  9. To establish a minimum safe and biologically effective dose [ Time Frame: 7 days ]
    Assess the CD117 receptor occupancy in circulating leukemic blasts

  10. To establish a minimum safe and biologically effective dose [ Time Frame: 21 days ]
    The incidence of qualifying protocol-defined dose-limiting toxicities

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participant must have a World Health Organization (WHO)-defined diagnosis of R/R AML and meet one of the following criteria:

    - The participant has experienced primary AML induction failure or R/R AML


    - The participant has a WHO-defined diagnosis of MDS-EB and has failed/is refractory to HMA


    - Presence of MRD in morphologic CR

  2. CD117+ based on IHC or flow cytometry
  3. Participant must have an identified HSC donor (related donor or unrelated donor), haplo-identical transplant donor, or umbilical blood donor.
  4. Participant's Eastern Cooperative Oncology Group (ECOG) performance status must be ≤2.
  5. Participant must have adequate baseline hepatic function. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) ≤2 x upper limit of normal (ULN), and serum bilirubin ≤1.5 x ULN.
  6. Estimated creatinine clearance ≥60 mL/min
  7. Adequate cardiac function as demonstrated by cardiac left ventricular ejection fraction ≥40% or perform New York Heart Association (NYHA) classification I and II

Exclusion Criteria:

  1. Acute promyelocytic leukemia (APL).
  2. Known active central nervous system (CNS) leukemia or chloroma (granulocyte sarcoma).
  3. Received HSCT within 6 months prior to dosing
  4. Received chimeric antigen-receptor cell therapies within 6 months prior to dosing
  5. Has active graft-versus-host disease (GVHD).
  6. Active hepatitis B (Hep-B) or hepatitis C (Hep-C) infection or history of human immunodeficiency virus (HIV).
  7. Participant with a QTc value >470 msec
  8. Participant has received another investigational drug or device within 14 days or 5 half-lives of dosing, whichever is longer.
  9. Participant has any clinically significant medical condition, which in the opinion of the Investigator may place the participant at an unacceptable risk.
  10. Active uncontrolled systemic bacterial, fungal, or viral infection
  11. Participant has a history of serious allergic reactions, which in the opinion of the Investigator may pose an increased risk of serious infusion reactions.
  12. Participant has had any systemic antileukemia treatment within 14 days except hydroxyurea, which is permitted until 24 hours prior to MGTA-117 dosing.
  13. Participant has received prior anti-CD117 antibody treatment.
  14. Participant has received gemtuzumab ozogamicin (Mylotarg) within the last 3 months prior to dosing.
  15. Participant has received recent monoclonal antibody as anti-leukemic therapy within the last 30 days or 5 half-lives, whichever is longer.
  16. Participant has received recent vaccination within the last 14 days prior to dosing.
  17. Participant has Grade 2 or higher electrolyte abnormality at screening

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05223699

Layout table for location information
United States, California
City of Hope
Duarte, California, United States, 91010
United States, Colorado
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, United States, 80218
United States, Florida
Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, Kansas
The University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New York
Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States, 14203
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
Magenta Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Magenta Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT05223699    
Other Study ID Numbers: 117-HEM-101
First Posted: February 4, 2022    Key Record Dates
Last Update Posted: February 9, 2023
Last Verified: February 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Magenta Therapeutics, Inc.:
Acute Myeloid Leukemia
Myelodysplasia-Excess Blasts
Hematopoietic stem cell transplant
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Neoplasms by Histologic Type
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions